Advanced Pathophysiology for APN
Dr. Butz & Dr. Chovan
Malignant Hyperthermia, Anesthesia, Dantrolene, Succinylcholine, Ryanodine receptor
Medicine and Health Sciences | Nursing
Malignant hyperthermia is a rare manifestation of a genetic mutation involving the ryanodine receptors. This mutation causes a sustained intracellular calcium release that is triggered by certain anesthetics such as depolarizing neuromuscular blockers and volatile gases. The extended release of calcium functions as a dangerous catalyst for hyper-metabolism that will lead to rapid death if unrecognized and untreated. Current treatment involves the drug dantrolene in tandem with symptomatic management in the intensive care setting. Symptomatic treatment may likely involve rapid cooling, fluid resuscitation, electrolyte management, and mechanical ventilation until symptoms resolve. A literature review of malignant hyperthermia is of vital importance due to its extreme rarity. Familiarity and competency are correlative. Thus, the more often practitioners receive education on malignant hyperthermia, the more success they will have in treating and preventing death wherever it may occur.
Colangelo, Nicholas, "Malignant Hyperthermia" (2020). Nursing Student Class Projects (Formerly MSN). 438.